research use only
Cat.No.S8249
| Related Targets | JAK TGF-beta/Smad Wnt/beta-catenin ERK GSK-3 ROCK PKA Secretase STAT Casein Kinase |
|---|---|
| Other Hedgehog/Smoothened Inhibitors | SAG (Smoothened Agonist) Hydrochloride Purmorphamine Cyclopamine (11-Deoxojervine) GANT61 SAG (Smoothened Agonist) SANT-1 BMS-833923 Taladegib (LY2940680) Ciliobrevin D Jervine |
|
In vitro |
DMSO
: 71 mg/mL
(198.22 mM)
Ethanol : 1 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 358.18 | Formula | C17H9Cl2N3O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 302803-72-1 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Hedgehog Pathway Inhibitor 4 | Smiles | C1=CC=C2C(=C1)C(=O)NC(=N2)C(=C(C3=C(C=C(C=C3)Cl)Cl)O)C#N | ||
| Targets/IC50/Ki |
Hedgehog
|
|---|---|
| In vitro |
HPI-4 (Ciliobrevin A) does not directly target Smo. It counteracts the activities of endogenous Gli1 and Gli2 but does not directly act on transcription factor GLIs. This compound significantly inhibited the proliferation of these neuronal progenitors, as measured by histone H3 phosphorylation (pH3) levels. It also reduced cellular levels of cyclin D1 protein and Gli1, Gli2, and N-Myc transcripts in the Cerebellar Granule Neuron Precursors. It acts by perturbing ciliogenesis. Treatment with this inhibitor could significantly decrease human chondrosarcoma cell proliferation, invasion and migration ability. Furthermore, it could distinctly disturb HH pathway-mediated ciliogenesis and suppress primary cilia-related protein intraflagellar transport protein IFT88 expression. HH downstream effect molecular GLI2 was restrained to block parathyroid hormone-related protein and affect MAPK/ERK-regulated matrix metalloproteinases (MMP2 and MMP9). It is also a small molecule inhibitor of the catalytic heavy chain subunit of cytoplasmic dynein.
|
| In vivo |
In a zebrafish model, treatment with HPI-4 (Ciliobrevin A), a ciliogenesis inhibitor, effectively prevented pancreatic fibrosis and destruction.
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | β-catenin |
|
26515592 |
| Growth inhibition assay | Cell viability |
|
26515592 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.